These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms. Halliday GM; McCann H Exp Neurol; 2008 Jan; 209(1):12-21. PubMed ID: 17706644 [TBL] [Abstract][Full Text] [Related]
23. Bioinorganic chemistry of Parkinson's disease: structural determinants for the copper-mediated amyloid formation of alpha-synuclein. Binolfi A; Rodriguez EE; Valensin D; D'Amelio N; Ippoliti E; Obal G; Duran R; Magistrato A; Pritsch O; Zweckstetter M; Valensin G; Carloni P; Quintanar L; Griesinger C; Fernández CO Inorg Chem; 2010 Nov; 49(22):10668-79. PubMed ID: 20964419 [TBL] [Abstract][Full Text] [Related]
24. DnaK/DnaJ/GrpE of Hsp70 system have differing effects on alpha-synuclein fibrillation involved in Parkinson's disease. Ahmad A Int J Biol Macromol; 2010 Mar; 46(2):275-9. PubMed ID: 20060408 [TBL] [Abstract][Full Text] [Related]
25. Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro. Hirohata M; Ono K; Morinaga A; Ikeda T; Yamada M Exp Neurol; 2009 Jun; 217(2):434-9. PubMed ID: 19289119 [TBL] [Abstract][Full Text] [Related]
26. Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins. Schnack C; Danzer KM; Hengerer B; Gillardon F Neuroscience; 2008 Jul; 154(4):1450-7. PubMed ID: 18541383 [TBL] [Abstract][Full Text] [Related]
27. Alpha-synuclein aggregation variable temperature and variable pH kinetic data: a re-analysis using the Finke-Watzky 2-step model of nucleation and autocatalytic growth. Morris AM; Finke RG Biophys Chem; 2009 Mar; 140(1-3):9-15. PubMed ID: 19101068 [TBL] [Abstract][Full Text] [Related]
28. A new perspective in Parkinson's disease, chaperone-mediated autophagy. Li B; Zhang Y; Yuan Y; Chen N Parkinsonism Relat Disord; 2011 May; 17(4):231-5. PubMed ID: 21215675 [TBL] [Abstract][Full Text] [Related]
29. Proteomics of Caenorhabditis elegans over-expressing human alpha-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages. Ichibangase T; Saimaru H; Takamura N; Kuwahara T; Koyama A; Iwatsubo T; Imai K Biomed Chromatogr; 2008 Mar; 22(3):232-4. PubMed ID: 17939164 [TBL] [Abstract][Full Text] [Related]
30. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420 [TBL] [Abstract][Full Text] [Related]
31. Membrane binding of oligomeric alpha-synuclein depends on bilayer charge and packing. van Rooijen BD; Claessens MM; Subramaniam V FEBS Lett; 2008 Nov; 582(27):3788-92. PubMed ID: 18930058 [TBL] [Abstract][Full Text] [Related]
32. Role of advanced glycation on aggregation and DNA binding properties of α-synuclein. Padmaraju V; Bhaskar JJ; Prasada Rao UJ; Salimath PV; Rao KS J Alzheimers Dis; 2011; 24 Suppl 2():211-21. PubMed ID: 21441659 [TBL] [Abstract][Full Text] [Related]
33. Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein. Kobayashi M; Kim J; Kobayashi N; Han S; Nakamura C; Ikebukuro K; Sode K Biochem Biophys Res Commun; 2006 Oct; 349(3):1139-44. PubMed ID: 16962995 [TBL] [Abstract][Full Text] [Related]
34. PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson's disease-related protein. Rekas A; Lo V; Gadd GE; Cappai R; Yun SI Macromol Biosci; 2009 Mar; 9(3):230-8. PubMed ID: 19116892 [TBL] [Abstract][Full Text] [Related]
35. Targeting alpha-synuclein in Parkinson's disease. Kapurniotu A Chem Biol; 2004 Nov; 11(11):1476-8. PubMed ID: 15555995 [TBL] [Abstract][Full Text] [Related]
36. Alpha-synuclein and its role in metal binding: relevance to Parkinson's disease. Wright JA; Brown DR J Neurosci Res; 2008 Feb; 86(3):496-503. PubMed ID: 17705291 [TBL] [Abstract][Full Text] [Related]
37. Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease. Arreguin S; Nelson P; Padway S; Shirazi M; Pierpont C J Inorg Biochem; 2009 Jan; 103(1):87-93. PubMed ID: 18976814 [TBL] [Abstract][Full Text] [Related]
38. Characterization of fibrillation process of alpha-synuclein at the initial stage. Tashiro M; Kojima M; Kihara H; Kasai K; Kamiyoshihara T; Uéda K; Shimotakahara S Biochem Biophys Res Commun; 2008 May; 369(3):910-4. PubMed ID: 18329380 [TBL] [Abstract][Full Text] [Related]
39. Copper and iron ions accelerate the prion-like propagation of α-synuclein: A vicious cycle in Parkinson's disease. Li Y; Yang C; Wang S; Yang D; Zhang Y; Xu L; Ma L; Zheng J; Petersen RB; Zheng L; Chen H; Huang K Int J Biol Macromol; 2020 Nov; 163():562-573. PubMed ID: 32629061 [TBL] [Abstract][Full Text] [Related]